Shaalan Beg MD MBA FASCO
@ShaalanBeg
Followers
7K
Following
26K
Media
1K
Statuses
17K
Reimagining cancer clinical trials. Foodie, family guy, digital health. FCOI: https://t.co/CtEt9hUmRB
Dallas, Texas
Joined February 2015
Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with
1
45
135
💯
Things that are not working (and are sometimes unethical) in phase 1 clinical trials: 1) sponsors employing eligibility criteria that aren't in the protocol; 2) sponsors asking investigators to submit multiple eligible patients for slots and cherry picking the ones they want 1/2
0
0
0
🚨 ATTN. New Jersey: MIKIE SHERRILL… - Refuses to commit that she won’t raise New Jersey’s sales tax. - Her plan will “cost you an arm and a leg, but if you’re a good person, YOU’LL DO IT.” As Governor, Mikie Sherrill will make YOU PAY! Vote AGAINST her on 11/4.
5
29
83
A refresher on the algorithm for MMR/MSI testing and genetics referral for Lynch Syndrome. @TheGutOncLab
4
26
91
Always enjoy learning from @JoshSmithMDPhD, Prof & Chair of Colorectal Surg at MDACC, & JANUS PI! We discuss: -JANUS (When will results report? Secret to crushing enrollment)? -Improving response eval & surveillance for non-op -Microbiome -& more! TY, Josh! Full link below.
3
13
35
Interesting findings from Dr. Joseph Unger at #ASCOQLTY25: “The special role of federal sponsorship in the design and conduct of drug or biological agent cancer treatment clinical trials.” https://t.co/0gqU9kCGuh
@ASCO @JCO_ASCO @JAMAOnc
#Cancer #ClinicalTrials
@DrJoeUnger
1
4
21
Phenomenal presentation by Dr. Cris Bergerot at #ASCOQLTY25 today! “Building Bridges: Collaborative Efforts to Transform Cancer Supportive Care.” https://t.co/RuNsSjLDVZ
@ASCO @JCO_ASCO @myCARG @crisbergerot
#PallOnc #GeriOnc #PalliativeCare #Geriatrics
1
9
28
In RAPIDO, higher LRR w short course TNT confined to pts undergoing sphincter-preserving surg (12 v 5%), w distal resection margin <1cm as predictor. Suggests need to re-eval safe margin & consider basing surg off original tumor extent. Caveat: post hoc, exploratory analysis.
Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial ➡️ https://t.co/WvgTEZvwft The difference in LRR between TNT and CRT mainly occurred in patients treated with
2
43
111
Inspiring talk by Dr. @Areejmd on digital innovation in palliative care Technology as a bridge to more accessible and person-centered support @ASCO #ASCOQLTY25
0
4
20
Great to hear an expert discussion on #FinancialToxicity from @EthicsdoctorP at #ASCOQLTY25 this afternoon! https://t.co/8zid9FHPa1
@ASCO @JCO_ASCO @JCOOP_ASCO
#PallOnc #SuppOnc #CancerResearch
1
4
20
Excellent presentation by @ryanhuey at #ASCOQLTY25 today: “Performance characteristics of CMS' OP-35 quality measure: Sensitive but not specific.” https://t.co/KlnAUI2Lt2
@ASCO @JCO_ASCO @JCOOP_ASCO @JAMAOnc @MDAndersonNews
#CancerCare #CancerResearch
1
8
21
We will face a shortage of oncologists as projected cancer cases rise and number of oncologists decreasing relative to demand. 25% of oncologists are 64y and older. Number of oncologists currently on pace to meet only 29% of demand in next 12 years. Gaps will widen.
16
84
191
Let me introduce you to the typical patient who is able to meet all 40 or so cancer clinical trial eligibility criteria of a usual sponsored trial + allow me to bring to your attention this great paper by @bherzbergmd (open access) highlighting the very restrictive nature of
6
7
42
In a world where the expectation is to be available at all times, a @NobelPrize laureate is teaching us more than just his work on T-Regs ✨ 👏 https://t.co/0i1hDxJCC9
1
5
22
One page takeaway/summary on @FDAOncology approval for Atezo + Lurbinectedin based off IMForte on October 2, 2025 and our discussion w/ @StephenVLiu @ipreeshagul and @LealTiciana on Extensive stage small cell lung cancer! #OncTwitter #MedTwitter #lcsm @OncUpdates
Lurbinectedin is now approved in 1L for ES-SCLC based off #IMForte! We had a chance to discuss the trial, findings, AE's and management w/ @ipreeshagul @StephenVLiu & @LealTiciana Full 🗣️: ⭐️ https://t.co/esrLBPn2Rm ⭐️ On “Oncology Brothers” podcast #OncTwitter #lcsm
1
15
41
~2 wks to #ESMO25! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge
#OncTwitter @myESMO @OncoAlert
2
73
199
Misinformation and the AMA Controversy: Part 2 https://t.co/kjeJLzSnow via @YouTube If you haven't seen the update on @ehlJAMA story, the full video of part 2 on #HealthcareUnfiltered is streaming on my YouTube. Check it out and join the conversation.
1
2
3
It’s Oct 1. Medicare-funded #telehealth has now expired. Farewell to virtual visits for seniors. Call your congressional teams! #advocacy
A program that allowed Medicare recipients to access telehealth services is about to end, leaving millions of seniors unable to access the care that allowed them to avoid long drives and crowded waiting rooms https://t.co/wCpJl5AGIR
1
5
10
#PallOnc exploration in #GIonc for @MASCC_JSCC
#pancsm face barriers to #InformedDecisions 🎓Knowledge gaps 🗣️Rushed communication 🫠Information overload Decision aids and patient advocates ⬆️ understanding, coping, and shared decisions 🔗:
link.springer.com
Supportive Care in Cancer - Informed decision-making is an essential component of shared decision-making between patients and their cancer teams that promotes patient comprehension of their disease...
0
8
18
I had the opportunity to mentor some promising medical students on an NCDB study: "Exploring Demographic, Prognostic, and Socioeconomic Determinants of Survival in Lymphocyte-rich Classical Hodgkin Lymphoma: A National Cancer Database Study" https://t.co/IHzsqCeqRc
ar.iiarjournals.org
Background/Aim: Lymphocyte-rich classical Hodgkin lymphoma (LR-cHL) is a rare subtype of Hodgkin lymphoma characterized by a marked absence of neutrophils and eosinophils in its T-cell microenviron...
1
3
12
RadOncReview ftw again. Thank you @jryckman3 🙏. Incredible resource. GI highlights below. #ASTRO25
Our “Best Of” #ASTRO25 abstract summary is out! 🦾🎯 Featuring plenaries, late-breaking abstracts, and select scientific highlights. I'm sure we missed plenty of gems - what would you add? 👇
3
22
75